Stock Report: Optimer Pharmaceuticals Inc. (OPTR) Report Updated: May 20, 2013 | Print This Page

Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on development and commercialization of pharmaceutical products. It offers fidaxomicin tablets, an antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). The company sells its fidaxomicin products through wholesalers to hospitals, retail, and specialty pharmacies in the United States. It also has fidaxomicin under Phase IIIB clinical trials for the treatment of CDAD prophylaxis and CDAD in oncology patients; and under Phase II clinical trials for the treatment of pediatric CDAD treatment. In addition, the company has Solithromycin product under Phase II clinical trials for the treatment of respiratory tract infections; and OPT-822/821 product under Phase II/III clinical trials for the treatment of breast cancer. It has collaborative agreements with Cubist Pharmaceuticals, Inc.; Astellas Pharma Europe Ltd.; Par Pharmaceuticals, Inc.; Biocon Limited; Patheon Inc.; Cempra Pharmaceuticals, Inc.; Optimer Biotechnology, Inc.; Memorial Sloan-Kettering Cancer Center; and Scripps Research Institute. The company was founded in 1998 and is based in San Diego, California.